Acetildenafil

Acetildenafil, also called Hongdenafil, is a sildenafil-related compound discussed for firmer erections. Reports include striking benefit, weak response and unwanted effects, often alongside other drugs. These accounts do not establish safety or effectiveness.

What Acetildenafil is

• A distinct sildenafil analogue. It belongs to the PDE5-inhibitor discussion, but it is a separate chemical identity. FDA’s substance registry maps Acetildenafil and Hongdenafil to UNII TP0E2BW57H and CAS 831217-01-7; that listing does not mean FDA approval. Official context
• A name on a packet does not verify its contents. Analytical researchers have also found Acetildenafil in products presented as herbal sexual enhancers. Those mixtures and the powders described online cannot be assumed to contain the same ingredients or strength. Official context

Benefits and disappointments people report

• Easier erections and renewed sexual confidence. The Erowid author described a markedly better sexual experience after earlier difficulty, with cannabis also involved. That is a personal outcome, not proof of increased desire or restored vascular health. Personal report
• Flushing can occur without clear benefit. beez69 found oral Acetildenafil unimpressive despite previously liking sildenafil and tadalafil. Feeling a bodily effect did not reliably translate into the desired erection response. Personal report

How the comparisons can mislead

• PDE5 inhibition concerns the erection response. Sildenafil’s label describes preserving cGMP, a signal that helps blood vessels relax during sexual stimulation. This explains the comparison; it does not establish Acetildenafil’s potency or make equal milligrams interchangeable. Official context
• The tadalafil comparison is partly hearsay. Acid4Blood compared the duration with tadalafil while acknowledging never having tried tadalafil. Other replies discuss Cialis itself, so their experiences cannot simply be reassigned to Acetildenafil. Personal report

Doses people discuss

All amounts are historical self-reports in milligrams (mg), not recommended doses or a low-to-high ladder.

• 15 mg total oral; 25, 50 and 100 mg with route unspecified. PowerFarts reported three 5 mg amounts with several other substances. Jackmeoff reported weaker benefit at 25 mg, preferred 50 mg, and found 100 mg uncomfortably prolonged; these are different people and contexts. Personal report Personal report
• 16–17 mg cumulative oral; 35 mg in another session. technorunner reported benefit after 5 + 5 + 6–7 mg with MPA, and after 35 mg with alcohol and amphetamine. Later sedative co-use clouded duration. Personal report
• 150 mg oral capsule in one Erowid account. This unusually high report included cannabis and earlier unsuccessful experimentation. It is neither a usual amount nor evidence for a safe ceiling. Personal report
• 100 mg oral and 160 mg rectal are separate observations. beez69 reported uncertain oral benefit; a later stimulant-associated rectal session totaled 100 + 60 mg. The account cannot establish superior absorption or route equivalence. Personal report

Half-life

• No supported human half-life in these reports. They describe sexual response, not serial blood measurements. Neither similarity to sildenafil nor a next-day effect supplies an Acetildenafil clearance value. Personal report Personal report

When people noticed a change

• 45–60 minutes in the Erowid oral account. This was the author’s first noticed response after the reported 150 mg capsule, not a measured blood peak or a general onset estimate. Personal report
• Repeated amounts complicate faster claims. technorunner’s roughly 20-minute change followed a third oral amount and earlier nonresponse with MPA, rather than a fresh single dose. Personal report

How long effects were reported

• Over four hours observed; 5–8 hours estimated. The Erowid author’s latter figure was a guess, with little apparent effect next morning. Neither number measures elimination. Personal report
• Next-day effects in a separate stimulant account. Jackmeoff described residual benefit after 50 mg and uncomfortable hardness lasting 24 hours beyond stimulant effects after 100 mg. Personal report
• A three-day claim came from a mixed capsule. Acid4Blood recalled a herbal combination with unknown strength; it cannot establish pure Acetildenafil’s duration. Personal report

Repeated use and time off

• No documented weeks-on, weeks-off schedule. These threads concern sexual occasions and experiments. They do not establish a tolerance-reset interval, safe daily use or a repeat-use calendar. Personal report Personal report
• Expected tolerance was speculation. The Erowid author wondered whether benefit would fade; no later follow-up in that report confirms that it did. Personal report

What can outweigh the benefit

• Head pressure increased with amount. The Erowid author reported stronger head and sinus sensations at 150 mg than 100 mg. Personal report
• Headache and painful nasal exposure appear in the reports. technorunner described burning and headache after 15–17 mg intranasally, despite later broadly claiming no side effects. Personal report
• An erection that persists beyond four hours needs emergency care. The sildenafil label also flags sudden vision or hearing loss for prompt medical attention. Prolonged-effect stories should never be read as reassurance that a continuous erection is harmless. Official context
• Nitrates, nitrite poppers and riociguat are major PDE5 interaction concerns. Sildenafil labeling prohibits these combinations and warns about added blood-pressure lowering with other medicines. This is class-based caution, not an Acetildenafil interaction trial; its unknown clearance provides no reliable waiting interval. Official context
• A clinical report described loss of balance and falls. A 28-year-old developed these symptoms after eight consecutive days using a sexual-enhancement product containing Acetildenafil. The 2007 report raises a serious signal, but does not prove isolated Acetildenafil caused it or tell us how often it happens. Official context

What the community accounts actually show

• Co-use changes the interpretation. PowerFarts’ seven-hour session involved ethylphenidate, bupropion, alcohol and cannabis. technorunner slept through a 30 mg trial with diclazepam; that is uninterpretable, not demonstrated failure. Personal report Personal report
• Stimulant-related difficulty was not consistently overcome. The Erowid author reported no erection response with 100 mg Acetildenafil plus 3-FPM, and also tried sildenafil co-use. These histories cannot support a reliable rescue combination. Personal report
• A same-author correction matters. maxade praised 100 mg, then called it excessive in the next post. MilzyWilzy’s favorable partner account and suggested amounts are secondhand; neither establishes a population-wide dose. Personal report Bluelight
• Packaging and borrowed advice are not dose evidence. The older thread mentions 110 mg pills and repeats general PDE5 instructions from another forum. The poster themselves questioned that extrapolation; a label strength and repeated advice are not two independent successful trials. Bluelight
• Changing route did not isolate the cause. beez69’s later rectal improvement came with stimulants and repeated administration. Their explanations involving absorption, weak material or formulation remained guesses, and the account does not validate those routes. Personal report